Celadon Pharmaceuticals PLC Total Assets
Celadon Pharmaceuticals PLC total assets. Based on the latest financial reports, Celadon Pharmaceuticals PLC (CEL) holds total assets worth GBX8.46 Million GBX (≈ $1.03K USD) as of June 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Celadon Pharmaceuticals PLC (CEL) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Celadon Pharmaceuticals PLC (2019–2023)
Total assets of Celadon Pharmaceuticals PLC from 2019 to 2023. This chart illustrates how Celadon Pharmaceuticals PLC's total assets have evolved over time, based on quarterly financial data. See Celadon Pharmaceuticals PLC (CEL) share price today for real-time trading data and today's change.
Celadon Pharmaceuticals PLC - Asset Composition Analysis
Celadon Pharmaceuticals PLC Total Assets Breakdown (December 2023)
Celadon Pharmaceuticals PLC total assets breakdown as of December 2023. Celadon Pharmaceuticals PLC's total assets of GBX8.46 Million consist of 27.1% current assets and 72.9% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 13.7% |
| Accounts Receivable | GBX75.00K | 0.8% |
| Inventory | GBX100.00K | 1.1% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX248.00K | 2.7% |
| Goodwill | GBX80.00K | 0.9% |
Asset Composition Trend (2019–2023)
This chart illustrates how Celadon Pharmaceuticals PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Celadon Pharmaceuticals PLC current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Celadon Pharmaceuticals PLC's current assets represent 27.1% of total assets in 2023, an increase from 0.1% in 2019.
- Cash Position: Cash and equivalents constituted 13.7% of total assets in 2023, up from 0.1% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 2.7% of total assets.
Celadon Pharmaceuticals PLC Competitors by Total Assets
Key competitors of Celadon Pharmaceuticals PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Porton Fine Chemicals Ltd
SHE:300363
|
China | CN¥8.58 Billion |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA
|
India | Rs135.21 Billion |
Celadon Pharmaceuticals PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.92 | 1.86 | 143.85 |
| Quick Ratio | 1.41 | 1.84 | 143.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX808.00K | GBX1.20 Million | GBX5.72 Million |
Celadon Pharmaceuticals PLC - Advanced Valuation Insights
This section examines the relationship between Celadon Pharmaceuticals PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.80 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -30.4% |
| Total Assets | GBX9.22 Million |
| Market Capitalization | $112.25K USD |
Valuation Analysis
Below Book Valuation: The market values Celadon Pharmaceuticals PLC's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Celadon Pharmaceuticals PLC's assets decreased by 30.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Celadon Pharmaceuticals PLC (2019–2023)
The table below shows the annual total assets of Celadon Pharmaceuticals PLC from 2019 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | GBX9.22 Million ≈ $1.12K |
-30.41% |
| 2022-12-31 | GBX13.25 Million ≈ $1.61K |
+100.53% |
| 2021-12-31 | GBX6.61 Million ≈ $803.99 |
+71.59% |
| 2020-12-31 | GBX3.85 Million ≈ $468.56 |
+54.74% |
| 2019-12-31 | GBX2.49 Million ≈ $302.81 |
-- |
About Celadon Pharmaceuticals PLC
Celadon Pharmaceuticals Plc engages in the research, cultivation, manufacturing, and sale of cannabis-based medicines. The company primarily focuses on growing indoor hydroponic cannabis for use in medicinal products. Its products used to treat chronic pain, as well as autism spectrum disorders. Celadon Pharmaceuticals Plc was founded in 2018 and is headquartered in London, the United Kingdom.